Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156559 · ClinicalTrials.gov registry record
MMR and Varicella Vaccine in Premature Infants
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 32
- Enrollment target
NCT00156559: Completed study, sponsored by University of Rochester.
NCT00156559 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00156559 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 month-old children born at \<29 weeks gestation, when compared to full-term infants, as measured by the relevant viral serologies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-05 |
What the finished NCT00156559 record still lists
NCT00156559 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00156559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00156559 about?
NCT00156559 is a clinical study titled "MMR and Varicella Vaccine in Premature Infants". This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 ...
What is the current status of trial NCT00156559?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2004-01. Estimated completion is 2005-05.
Who is sponsoring clinical trial NCT00156559?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia